Vacuna Ads-nCoV de CanSino BiologyA single biological dose is currently being applied to teachers and education personnel, which has also been administered in different municipalities of the country for the sake of Elderly, Will have to be boosted at six months of age due to the reduced immunity it provides against the virus SARS-CoV-2According to the clinical trial currently underway.
A few days ago, the Department of Infectious Diseases at the Salvador Zuberan National Institute of Medical Sciences and Nutrition (INCMNSZ), One of the Mexican institutions that participated in the clinical trial since the end of 2020, contacted the participating volunteers by e-mail to give them the following notice:
“The last information is with this [la vacuna Ads-nCoV de CanSino] And others have already been approved by the regulatory bodies United State, The European UnionAnd the Coffibress (Mexico), and other parts of the world, show that their immunity drops dramatically in six months. For this reason, it was decided that the people who received the placebo in this study would get the first dose of Ads-nCoV vaccine and in the participants who received the vaccine, a second dose would be given. “
Read also: AMLO: Vaccination for 40-49 year olds will start in July
This information about CanSino’s effectiveness over time, which has not been officially released, is being added to data from other vaccines, whose laboratories have already warned that people who have been vaccinated should be immunized over the course of months.
Pfizer, a 9-month vaccine
At the end of April, the German company BioNTech created by Pfizer One of the vaccines ARN Messenger against Covid-19, He confirmed in a videoconference that a third dose between 9 and 12 months after the first injection would be necessary to prevent the vaccine from decreasing effectiveness.
Not long ago, Pfizer’s executive management commented to US media about the need for a third dose. According to BioNTech, the effectiveness of its vaccine drops from 95% to 91% in six months as antibody production decreases.
In the letter to volunteers for clinical trials, signed by the physician Guillermo M Ruiz Palacios, Principal investigator in the department of infectious diseases at INCMNSZ, said that CanSino vaccine immunization drops “significantly” in six months, but the percentage has not been determined.
Carmen Amesqua, Head of Communication and Participation at INCMNSZ, commented that the institute must have permission from the Ministry of Health to report a clinical trial on the CanSino vaccine. At the Ministry of Health Thalia Monroy, Deputy Director of Information, did not respond to an email asking the clinical trial investigator for a report, among other things, of how low CanSino vaccine immunity was in six months.
Read also: Should I go on an empty stomach to get the COVID-19 vaccine?
First warning from China
Last April, Asian media and international agencies reported that Zhao Fu, director of the Chinese Center for Disease Control and Prevention, admitted that the efficacy of vaccines developed by his country is less than that of Pfizer. modern, For example.
Sinovac, Sinopharm and CanSino are the Chinese brands currently applied in the world which are also in the stage of clinical studies in many countries. CanSino, one of those implemented in Mexico (the other being Sinovac), has an efficacy rate of 75%, according to Chinese sources.
According to the news agency EFEA few weeks ago, Gao Fu commented to the newspaper Global Times, The post in your country: “Protection rates for all the world’s vaccines are sometimes high and sometimes low. Improving their efficacy is a question that scientists around the world have to ask themselves. In this regard, I suggest that we consider adjusting the vaccination process, as well as the number of doses and durations, And the adoption of serial vaccination, with different types of antigens ”.
Around, Globalism He asked the Health Ministry if the CanSino vaccine could be combined with other brands when a booster dose was required, which is now known six months later, but there was no response. What implications will this result have on the immunity in six months that CanSino bio-provide in the current national vaccination plan? Was there another question that was asked.
Read also: Investigation of the “hangover” discovered in AstraZeneca vaccines
Although the Ministry of Health did not respond, it will undoubtedly have an impact on vaccination plans. On December 9, 2021, Foreign Minister Marcelo Ebrard reported on Twitter that Jorge Alcoser, Minister of Health; Xuefeng Yu, President of CanSino Biologics Inc; s Jerome Piguet, Of Latam Pharma Innovative Ventures, on that day pre-purchase agreement for 35 million doses of CanSino vaccines.
This biological species, which is taken in a single dose and has the advantage that it can be kept in regular refrigerators, has been practically applied to the population since the start of the national vaccination plan. As of May 20, 4 million 649 thousand 440 doses of CanSino have been received in the country. All people vaccinated with this biological material and vaccinated in the first half of the year will have to receive a second dose before the end of 2021.
In the case of the Pfizer vaccine, those who received these two biological doses, in 9 months, would have to receive a third strength. Data on loss of efficacy and consequent reimplantation of doses and intervals between Sinovac vaccines are still unknown. AstraZeneca s Sputnik f, Which are other trademarks currently applied in Mexico.
4 million 649 thousand 440 doses of CanSino were received in the country as of May 20.
75% effectiveness rate Which has the CanSino vaccine, one of those applied in Mexico.